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Abstract
Background: Expressions of various biomarkers in non-small cell lung cancer (NSCLC) have been linked with the prog-
nosis and involvement of mediastinal lymph nodes.
Methods: In this study, we utilized recursive partitioning analysis (RPA) by using P53, c-erb-B2, and P-glycoprotein (PGP) 
expressions evaluated by immunohistochemistry to estimate retrospectively the likelihood of the occult N2 mediastinal 
lymph node involvement in patients with operable NSCLC.
Results: In univariate tests, immunohistochemical staining of the primary tumor for these 3 markers in 61 patients undergo-
ing surgery revealed no direct relationship with the N2 involvement. However, RPA demonstrated in patients aged 75 and 
with 4 mediastinal lymph nodes removed that, high PGP expression frequency (20%) predicted an increased likelihood 
of the N2 involvement (46.7%, R
2 = 0.25). Univariate nominal logistic regression analysis revealed that RPA group afﬁ  li-
ation, and the number of mediastinal lymph nodes resected (logarithmic transformation) were associated with the metasta-
sis to N2 lymph nodes (χ
2 = 17.59, p = 0.0005, and χ
2 = 2.40, p = 0.0654, respectively). Multivariate analysis conﬁ  rmed that 
only RPA group afﬁ  liation predicted the N2 involvement (χ
2 = 14.63, p = 0.0022).
Conclusion: This study shows for the ﬁ  rst time that PGP expression of the primary tumor may help to predict the occult 
N2 mediastinal lymph node involvement in NSCLC. Thus, further research is required to understand whether PGP expres-
sion may aid in the decision process for preoperative mediastinoscopy.
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Background
NSCLC is a biologically diverse disease with over a hundred prognosticators unveiled so far [1]. Surgery 
is still the mainstay of treatment for the early stages of NSCLC, but, survival is still poor with surgery 
only for locally advanced disease: 5 year overall survival is 10%–15% in clinical microscopic N2, and 
2%–5% in clinical macroscopic N2 diseases [2]. Factors like serum-soluble intercellular adhesion 
molecule-1(ICAM-1) [3] and CEA levels, T stage, but not the mediastinal lymph node diameter on CT 
scan [4], expression of Caveolin-1, a tumor suppressor [5], and ampliﬁ  cation of c-myc gene [6] have 
all been found to correlate with the presence of N2 disease, some of them also implying worse prog-
nosis after surgery. In a previous study, our group showed in operable NSCLC that, different relation-
ships of P53 (a tumor suppressor), c-erb-B2 (an oncogene) and PGP (P-glycoprotein: a product of the 
multidrug resistance gene; MDR1), with the patient outcome may exist for different tumor histologies, 
again highlighting the heterogeneity in biological behavior [7]. In this study, we wanted to explore 
whether these 3 biomarkers also helped to predict the likelihood of occult N2 disease , in order to ﬁ  nd 
a new indication for mediastinoscopy.342
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Methods
Selection of patients
The patients were retrospectively selected from the 
database of the Thoracic Surgery department of 
Akdeniz University Medical Faculty Hospital, and all 
had curative resection for NSCLC. These patients, 
according to the guidelines of the treating institution, 
did not have clinical N2 or N3 disease by preoperative 
CT scans, and were deemed to have resectable disease 
by the treating surgeon. Patients had to have either 
mediastinal lymph node dissection or sampling at the 
time of surgery for inclusion into this study. All 
patients were staged with the help of chest and upper 
abdominal CT scanning, and in stage 3 disease bone 
scintigraphy was also requested. Only the patients 
operated within the thoracic surgery department at the 
Akdeniz University Hospital during the last 5 years 
(from 1.1.1998 to 31.12.2002) and with enough paraf-
ﬁ  n blocks remaining to perform all of the immuno-
histochemical studies in this study were retrospectively 
evaluated. Presence of nodal metastasis was evaluated 
by hematoxylin and eosin staining. The patients 
included in this study were from a subgroup of the 
previously published cohort from our center [7].
Immunohistochemistry
Five µm sections of parafﬁ  n blocks containing tumor 
tissue were deparafﬁ  nised and dehydrated, and then 
subjected to the procedure of antigen retrieval. Immu-
nohistochemical staining for PGP, P53 and c-erb-B2 
was conducted by using Dako (1/100 dilution), Neo-
marker (1/50 dilution), and Neomarker (1/300 dilu-
tion), respectively. Expression of the biomarkers were 
deﬁ  ned both by expression intensity (“0 to +”; none 
or minimal, and “++ to +++”; moderate or strong) if 
at least 5% of the cells were stained, or by expression 
frequency, deﬁ  ned as the ratio of positively staining 
cells among a total of tumor cells.
Statistical analysis
The immunohistochemical associates of N2 lymph 
node involvement were assessed by non-parametric 
tests, and by univariate logistic regression analysis. 
N2 lymph node involvement was chosen as the 
categorical response variable, and patient, disease 
factors and biomarker factors as predictor variables 
in the recursive partitioning analysis (RPA). In 
RPA, G^2 indicated the likelihood-ratio chi-square, 
which is actually twice the [natural log] entropy. 
Entropy is ∑-log (p) for each observation, where 
p is the probability (Prob) attributed to the response 
that occurred. The recursive partitioning analysis 
group membership, as well as the other variables 
in question were then also evaluated by univariate 
and multivariate nominal logistic regression analy-
sis. Variables with a p value of 0.10 in univariate 
logistic regression analysis were subjected to mul-
tivariate logistic regression analysis. Receiver 
operating curve (ROC) analysis was employed to 
show the accuracy of the classiﬁ  cation system 
based on RPA group affiliation to predict N2 
involvement. A p value of 0.05 was accepted to 
be signiﬁ  cant. JMP 5.0.1a (a business unit of SAS) 
was employed for the recursive partitioning analy-
sis, where as, SPSS 11.5.0 (SPSS Inc., Chicago, 
IL, USA) was used for the logistic regression 
analysis.
Results
General features
A total of 61 cases with a median age of 65, and 
86.9% male were selected for this study. A median 
of 8.6 lymph nodes were resected per each surgery. 
Occult N2 lymph node involvement was seen in 
16 cases (26.3%). PGP, c-erb-B2, and P53 were 
expressed in 42.7%, 49.3%, and 48.8% of tumor 
cells, respectively. T1N0, T2N0 and T3N0 stages 
were encountered in 5 (8%), 20 (33%) and 8 (13%) 
cases. Please, see Table 1 for details. The expres-
sion intensity and frequency of these 3 biomarkers 
were not associated with the mediastinal N2 lymph 
node involvement (details given in Table 2).
Recursive partitioning analysis 
of mediastinal N2 lymph node 
involvement
RPA analysis formed 4 groups of clinical relevance 
after 3 splits: 1; age 75, LN 4, PGP 20% 
(N2 probability = 46.7%), 2; age 75, LN 4, 
PGP 20% (N2 probability = 15.4%),3; age 75, 
LN 4 (N2 probability = 0%), 4; age 75 (N2 
probability = 0%). Thus, in age 75, LN 4 
patients, PGP expression 20% predicted a 32% 
more likelihood of an associated N2 disease as 
opposed to those with PGP expression 20%.This 
model had an R
2 of 0.25.
Likewise, in patients with N2 disease, RPA 
group 1 (age 75, LN 4, pgp 20%) comprised 343
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88% of cases, as opposed to 36% in those without 
N2 disease. (Refer to Figures 1 and 2 for details of 
RPA).
The corresponding sensitivity, specifity, false 
negative rate, and false positive rate of the model were 
47%, 89%, 14%, and 46%, respectively. In addition, 
the associated positive and negative predictive values 
for this model were 54% and 86%, in order.
Receiver operating curve (ROC) analysis 
yielded an area of 0.79 for N2 status prediction 
with RPA group afﬁ  liation.
Logistic regression analysis
for determinants of mediastinal N2 
involvement
Univariate nominal logistic regression analysis 
showed that RPA group afﬁ  liation, and the number 
of mediastinal lymph nodes resected (logarithmic 
transformation) were linked with the involvement 
of N2 lymph nodes (χ
2 = 17.59, p = 0.0005, and 
χ
2 = 2.40, p = 0.0654, respectively). Multivariate 
analysis also showed that RPA group afﬁ  liation 
was the only predictor of N2 involvement 
(χ
2 = 14.63, p = 0.0022). The details of logistic 
regression analysis are displayed in Table 2.
Discussion
We show in this study by RPA that the PGP 
expression was linked with the mediastinal N2 
lymph node involvement in a subgroup (43/61; 
71%) of patients with operable NSCLC. Studies 
in the literature have yielded conﬂ  icting results 
on the prognostic role of PGP in NSCLC. The 1st 
one claimed of no prognostic role, whereas the 
2nd one showed better prognosis with the 
increased expression of PGP [8, 9]. A previous 
report from our group was the 3rd one, and to our 
knowledge also the last one in the literature, that 
similarly showed no prognostic role for PGP in 
NSCLC [7]. To the best of our knowledge, there 
is no information in NSCLC on the relationship 
of PGP expression with the mediastinal lymph 
Table 1. Patient, disease and immunohistochemical features.
Features n(%)  Median/Mean  Range
Total 61  (100.0)
Patient factors
Age   65.0/65.2  44–84
Gender
 Female  8  (13.1)
 Male  53  (86.9)
Amount of smoking (pack-years)    45.0/46.9  0–100
Disease factors
Histology
  Squamous cell carcinoma  39 (63.9)
  Non-squamous cell carcinoma  22 (36.1)
T status
 1  8  (13.1)
 2  43  (70.5)
 3  9  (14.8)
 4  1  (1.6)
N status
  N0 and N1  45 (73.7)
 N2  16  (26.3)
Number of mediastinal lymph nodes resected    7.0/8.6  1–39
Immunohistochemical factors
 PGP  expression  intensity*    1/1.4  0–3
  PGP expression frequency (%)**    40/42.7  0–95
 c-erb-B2  expression  intensity*    1/1.4  0–2
  c-erb-B2 expression frequency (%)**    60/49.3  0–90
  P53 expression intensity*    2/1.7  0–3
  P53 expression frequency (%)**    50/48.8  0–95
*; magnitude of staining (0 to +++, over a scale of 3) 
**; % tumor cells stained with the speciﬁ  c marker344
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node involvement. This study shows a higher 
likelihood of N2 disease with higher expression 
of PGP. Interestingly, this relationship is not evi-
dent in the univariate analyses, but in the RPA. It 
is possible to speculate that high PGP expression 
in NSCLC may imply a more aggressive clinical 
behavior of cancer cells. This aggressive clinical 
behavior is possibly mediated via different mol-
ecules such as Y-box binding protein-1, as was 
also shown in breast cancer [10].
Table 2. Determinants of N2 mediastinal lymph node involvement.
Parameter Univariate  tests  Multivariate tests
 LR  χ2* p  LR  χ2* p
Patient factors
 Age  0.32  0.5711
  Gender (Female vs male)  0.01  0.9321
  Amount of smoking (pack-years)  0.13  0.7233
Disease factors
  Histology (Squamous vs non-squamous cell carcinoma)  0.02  0.8896
  T status (ordinal variable from 1 to 4)  5.19  0.1581
  Number of mediastinal lymph nodes resected   2.40  0.0654  0.44  0.5077
 (logarithmic  transformation)
Immunohistochemical factors
 PGP  expression  intensity**  0.09  0.7699
  PGP expression frequency (%)***  0.74  0.3913
 c-erb-B2  expression  intensity**  0.12  0.7348
  c-erb-B2 expression frequency (%)***  0.09  0.7693
  P53 expression intensity**  0.32  0.5708
  P53 expression frequency (%)***  0.01  0.9276
  Recursive partitioning analysis group
$ 17.59  0.0005  14.63  0.0022
*; Likelihood ratio Chi square
**; magnitude of staining (0 to +++, over a scale of 3)
***; % tumor cells stained with the speciﬁ  c marker
$; Recursive partitioning analysis group afﬁ  liation (of the 4 leaves formed by the model)
Figure 1. Tree view and leaf report for the recursive partitioning analysis model of mediastinal N2 lymph node involvement. 
LN: Lymph node, G^2:  the likelihood-ratio chi-square. Prob: the probability attributed to the response that occurred.
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We also demonstrated that younger age and higher 
number of mediastinal lymph nodes dissected were 
linked with the presence of N2 disease. This is in line 
with the fact that younger age is not a good prognos-
ticator in NSCLC patients treated with surgery [11, 
12]. Removing more than 3 mediastinal lymph nodes 
also apparently make it easier and more probable to 
catch microscopically involved N2 lymph nodes. In 
accordance, Keller et al also showed that with system-
atic mediastinal lymph node dissection, it was more 
probable to detect multilevel N2 disease [13].
There may be a number of shortcomings with 
this study; namely its retrospective nature and 
small size. However, we think the hypothetic role 
proposed in this study for PGP to predict N2 
disease warrants further research. In addition, 
although the proposed recursive p artitioning 
model had good negative predictive value (86%), 
its sensitivity should still be considered suboptimal 
(47%). Thus, this model may theoretically 
suggest those patients who may be spared from 
mediastinoscopy, but it still lacks power to 
identify the subgroup of patients who may 
need mediastinoscopy.
In short, our ﬁ  ndings suggest that even when 
clinical N2 disease is absent, PGP expression of the 
primary tumor may alert clinicians towards preop-
erative mediastinoscopy. Although, the general 
recommendation for microscopic N2 disease 
discovered at the time of surgery is surgical resec-
tion [14], we do not know whether neoadjuvant 
chemotherapy improves survival in this speciﬁ  c 
group of patients. Further larger clinical trials of 
prospective nature are needed to understand the 
importance of PGP expression to guide preoperative 
mediastinoscopy, and to select the optimal treat-
ment for microscopic N2 disease.
Conclusion
PGP expression of the primary tumor in operable 
NSCLC may prove useful in the prediction of N2 
disease. In this regard, prospective and larger 
clinical studies are needed to conclude further.
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Figure 2. Recursive partitioning analysis group and mediastinal N2 lymph node involvement.
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